All Information (Except Text) for S.1131 - Fair Accountability and Innovative Research Drug Pricing Act of 2017115th Congress (2017-2018)
|Sponsor:||Sen. Baldwin, Tammy [D-WI] (Introduced 05/16/2017)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 05/16/2017 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Actions Overview (1)
|05/16/2017||Introduced in Senate|
All Actions (1)
|05/16/2017||Read twice and referred to the Committee on Health, Education, Labor, and Pensions.|
Action By: Senate
|Sen. McCain, John [R-AZ]*||05/16/2017|
|Committee / Subcommittee||Date||Activity||Related Documents|
|Senate Health, Education, Labor, and Pensions||05/16/2017||Referred to|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
Latest Summary (1)
Introduced in Senate (05/16/2017)
Fair Accountability and Innovative Research Drug Pricing Act of 2017
This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products with a wholesale cost of $100 or more per month to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the cost of a drug over a 12-month period or a 25% or more increase over a 36-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Reports must contain specified information including pricing history and a justification for each price increase in the relevant period.
Manufacturers that do not submit a required report are subject to a civil penalty. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.